What is HC Wainwright’s Estimate for INO FY2024 Earnings?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – HC Wainwright lifted their FY2024 earnings estimates for Inovio Pharmaceuticals in a research note issued to investors on Monday, January 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($4.19) per share for the year, up from their prior estimate of ($4.39). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.41) EPS.

Other equities research analysts also recently issued reports about the stock. Oppenheimer lowered their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Royal Bank of Canada lowered their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday, November 15th. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.40.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.86 on Wednesday. The company has a market cap of $48.55 million, a PE ratio of -0.89 and a beta of 0.84. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The company has a 50-day simple moving average of $3.19 and a 200-day simple moving average of $5.97.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its stake in Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 3,630 shares during the period. MetLife Investment Management LLC grew its stake in Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 8,546 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Inovio Pharmaceuticals during the second quarter worth approximately $82,000. American Century Companies Inc. grew its stake in Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 12,100 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Inovio Pharmaceuticals during the third quarter worth approximately $71,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.